Jonas Agerlund Povlsen

Jonas Agerlund Povlsen

Auto-generated profile, based on publicly available information

Jonas Agerlund Povlsen

Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MPMia M. Pries-Heje
Mia M. Pries-Heje
CWChristoffer Wiingaard
Christoffer Wiingaard
NINikolaj Ihlemann
Nikolaj Ihlemann
SGSabine U. Gill
Sabine U. Gill
NBNiels E. Bruun
Niels E. Bruun
HBHenning Bundgaard
Henning Bundgaard
Step-down therapy with oral antibiotics has shown efficacy in some complex infectious diseases, including bone and joint infections1 and endocarditis,2 but data on longer-term outcomes are needed.3 In the Partial Oral Treatment of Endocarditis (POET) trial,2 step-down therapy with oral antibiotics after clinical stabilization of patients with endocarditis on the left side of the heart was shown to be noninferior to continued intravenous antibiotic therapy after 6 months (primary trial outcome),2 and no indications of treatment failure after 3 years were observed.4 Here we report the outcome of the POET trial more than 5 years after randomization (details of the trial design are provided in the protocol, available with the full text of this letter at NEJM.org).

30 May 2019 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LØLauge Østergaard
Lauge Østergaard
NBNiels Eske Bruun
Niels Eske Bruun
MVMarianne Voldstedlund
Marianne Voldstedlund
MAMagnus Arpi
Magnus Arpi
CAChristian Østergaard Andersen
Christian Østergaard Andersen
EFEmil Loldrup Fosbøl
Emil Loldrup Fosbøl
Increasing attention has been given to the risk of infective endocarditis (IE) in patients with certain blood stream infections (BSIs). Previous studies have been conducted on selected patient cohorts, yet unselected data are sparse. We aimed to investigate the prevalence of IE in BSIs with bacteria typically associated with IE. By crosslinking nationwide registries from 2010 to 2017, we identified patients with BSIs typically associated with IE: Enterococcus faecalis (E. faecalis), Staphylococcus aureus (S. aureus), Streptococcus spp., and coagulase negative staphylococci (CoNS) and examined the concurrent IE prevalence. A trend test was used to examine temporal changes in the prevalence of IE. In total 69 021, distributed with 15 350, 16 726, 19 251, and 17 694 BSIs were identified in the periods of 2010–2011, 2012–2013, 2014–2015, and 2016–2017, respectively. Patients with E. faecalis had the highest prevalence of IE (16.7%) followed by S. aureus (10.1%), Streptococcus spp. (7.3%), and CoNS (1.6%). Throughout the study period, the prevalence of IE among patients with E. faecalis and Streptococcus spp. increased significantly (P = 0.0005 and P = 0.03, respectively). Male patients had a higher prevalence of IE for E. faecalis, Streptococcus spp., and CoNS compared with females. A significant increase in the prevalence of IE was seen for E. faecalis, Streptococcus spp., and CoNS with increasing age. For E. faecalis BSI, 1 in 6 had IE, for S. aureus BSI 1 in 10 had IE, and for Streptococcus spp. 1 in 14 had IE. Our results suggest that screening for IE seems reasonable in patients with E. faecalis BSI, S. aureus BSI, or Streptococcus spp. BSI.

29 July 2022 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
AJAndreas Dalsgaard Jensen
Andreas Dalsgaard Jensen
LØLauge Østergaard
Lauge Østergaard
JPJeppe Kofoed Petersen
Jeppe Kofoed Petersen
PGPeter Laursen Graversen
Peter Laursen Graversen
JBJawad H. Butt
Jawad H. Butt
EFEmil L. Fosbøl
Emil L. Fosbøl
Background: Valve surgery guidelines for infective endocarditis (IE) are unchanged over decades and nationwide data about the use of valve surgery do not exist. Methods: We included patients with first-time IE (1999–2018) using Danish nationwide registries. Proportions of valve surgery were reported for calendar periods (1999–2003, 2004–2008, 2009–2013, 2014–2018). Comparing calendar periods in multivariable analyses, we computed likelihoods of valve surgery with logistic regression and rates of 30 day postoperative mortality with Cox regression. Results: We included 8804 patients with first-time IE; 1981 (22.5%) underwent surgery during admission, decreasing by calendar periods (N = 360 [24.4%], N = 483 [24.0%], N = 553 [23.5%], N = 585 [19.7%], P = < 0.001 for trend). For patients undergoing valve surgery, median age increased from 59.7 to 66.9 years (P ≤ 0.001) and the proportion of males increased from 67.8% to 72.6% (P = 0.008) from 1999–2003 to 2014–2018. Compared with 1999–2003, associated likelihoods of valve surgery were: Odds ratio (OR) = 1.14 (95% CI: 0.96–1.35), OR = 1.20 (95% CI: 1.02–1.42), and OR = 1.10 (95% CI: 0.93–1.29) in 2004–2008, 2009–2013, and 2014–2018, respectively. 30 day postoperative mortalities were: 12.7%, 12.8%, 6.9%, and 9.7% by calendar periods. Compared with 1999–2003, associated mortality rates were: Hazard ratio (HR) = 0.96 (95% CI: 0.65–1.41), HR = 0.43 (95% CI: 0.28–0.67), and HR = 0.55 (95% CI 0.37–0.83) in 2004–2008, 2009–2013, and 2014–2018, respectively. Conclusions: On a nationwide scale, 22.5% of patients with IE underwent valve surgery. Patient characteristics changed considerably and use of valve surgery decreased over time. The adjusted likelihood of valve surgery was similar between calendar periods with a trend towards an increase while rates of 30 day postoperative mortality decreased.

30 May 2018 in Journal of Proteome Research
Verified
Journal Article
Closed access
AEAnders Valdemar Edhager
Anders Valdemar Edhager
JPJonas Agerlund Povlsen
Jonas Agerlund Povlsen
BLBo Løfgren
Bo Løfgren
HBHans Erik Bøtker
Hans Erik Bøtker
JPJohan Palmfeldt
Johan Palmfeldt

1 November 2013 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
AAAsger Andersen
Asger Andersen
JPJonas Agerlund Povlsen
Jonas Agerlund Povlsen
HBHans Erik Bøtker
Hans Erik Bøtker
JNJens Erik Nielsen-Kudsk
Jens Erik Nielsen-Kudsk
Aims: We aimed to investigate the response to ischaemia–reperfusion (IR) and ischaemic pre-conditioning (IPC) in the hypertrophic and failing right heart. Methods and results: Male Wistar rats underwent sham operation, moderate pulmonary trunk banding (mPTB), or severe PTB (sPTB). Four weeks after surgery, hearts were quick-frozen (n = 28) for biochemical analysis of key salvage pathways or isolated and perfused in a Langendorff set-up (n = 46). We randomized perfused hearts to IPC (2 × 5 min of global ischaemia) or no preceding ischaemia (CON), before 40 min of global ischaemia and 120 min of reperfusion. The infarct size/area at risk (IS/AAR) ratio and post-ischaemic right ventricular (RV) function were used to evaluate the effect of IPC. mPTB induced compensated RV hypertrophy and sPTB induced RV hypertrophy with failure. Hypertrophy of the right ventricle increased IS in hearts from mPTB and sPTB animals compared with sham (IS/AAR, 73.1 ± 2.9% and 59.3 ± 2.4% vs. 35.6 ± 2.9%, P < 0.0001). IPC reduced IS in sham and mPTB hearts (IS/AAR, 35.6 ± 2.9% vs. 17.4 ± 1.2% and 73.1 ± 2.9% vs. 56.9 ± 3.5%, P < 0.01) and improved recovery of RV contractile function. IPC did not alter IS/AAR (59.3 ± 2.4% and 59.3 ± 2.9%, P = 0.999) or haemodynamic recovery in sPTB hearts. RV cyclic guanosine monophosphate (cGMP) and the cGMP-dependent protein kinase were increased after sPTB. Conclusion: Right ventricular hypertrophy increases IR injury. Cardioprotection by IPC is abolished in the failing but not the compensated hypertrophic right ventricle of the rat heart.

23 February 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMarie Vognstoft Hjortbak
Marie Vognstoft Hjortbak
JHJohanne Hjort
Johanne Hjort
JPJonas Agerlund Povlsen
Jonas Agerlund Povlsen
RJRebekka Vibjerg Jensen
Rebekka Vibjerg Jensen
NSNicolaj Brejnholdt Støttrup
Nicolaj Brejnholdt Støttrup
HBHans Erik Bøtker
Hans Erik Bøtker
Augmented mortality and morbidity following an acute myocardial infarction in patients with diabetes mellitus Type 2 (T2DM) may be caused by increased sensitivity to ischemia reperfusion (IR) injury or altered activation of endogenous cardioprotective pathways modified by T2DM per se or ischemic preconditioning (IPC). We aimed to investigate, whether the duration of T2DM influences sensitivity against IR injury and the efficacy of IPC, and how myocardial glucose oxidation rate was involved. Male Zucker diabetic fatty rats (homozygote (fa/fa)) at ages 6-(prediabetic), 12- (onset diabetes) and 24-weeks of age (late diabetes) and their age-matched non-diabetic controls (heterozygote (fa/+) were subjected to IR injury in the Langendorff model and randomised to IPC stimulus or control. T2DM rats were endogenously protected at onset of diabetes, as infarct size was lower in 12-weeks T2DM animals than in 6- (35±2% vs 53±4%; P = 0.006) and 24-weeks animals (35±2% vs 72±4%; P<0.0001). IPC reduced infarct size in all groups irrespective of the presence of T2DM and its duration (32±3%; 20±2%; 36±4% respectively; (ANOVA P<0.0001). Compared to prediabetic rats, myocardial glucose oxidation rates were reduced during stabilisation and early reperfusion at onset of T2DM, but these animals retained the ability to increase oxidation rate in late reperfusion. Late diabetic rats had low glucose oxidation rates throughout stabilisation and reperfusion. Despite inherent differences in sensitivity to IR injury, the cardioprotective effect of IPC was preserved in our animal model of pre-, early and late stage T2DM and associated with adaptations to myocardial glucose oxidation capacity.